Hilary Od Critchley

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10899287/publications.pdf

Version: 2024-02-01

88 papers 6,978 citations

76031 42 h-index 81 g-index

91 all docs 91 docs citations

times ranked

91

5702 citing authors

#	Article	IF	CITATIONS
1	Editorial on pregnancy and the SARS-CoV-2 pandemic. Physiological Reviews, 2022, , .	13.1	o
2	Counseling and surveillance of obstetrical risks for female childhood, adolescent, and young adultÂcancerÂsurvivors: recommendations fromÂtheÂlnternationalÂLate Effects of Childhood CancerÂGuidelineÂHarmonization Group. American Journal of Obstetrics and Gynecology, 2021, 224, 3-15.	0.7	35
3	Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy. New England Journal of Medicine, 2021, 384, 630-642.	13.9	99
4	The endometrial response to modulation of ligand-progesterone receptor pathways is reversible. Fertility and Sterility, 2021, 116, 882-895.	0.5	7
5	Menstruation: science and society. American Journal of Obstetrics and Gynecology, 2020, 223, 624-664.	0.7	149
6	Obesity and menstrual disorders. , 2020, , 171-177.		3
7	Abnormal uterine bleeding (including PALM COEIN classification). Obstetrics, Gynaecology and Reproductive Medicine, 2019, 29, 98-104.	0.1	7
8	Chronic pelvic pain in women: an embedded qualitative study to evaluate the perceived benefits of the meridian balance method electro-acupuncture treatment, health consultation and National Health Service standard care. British Journal of Pain, 2019, 13, 244-255.	0.7	1
9	Pelvic Chlamydial Infection Predisposes to Ectopic Pregnancy by Upregulating Integrin \hat{l}^21 to Promote Embryo-tubal Attachment. EBioMedicine, 2018, 29, 159-165.	2.7	16
10	A practical guide to preâ€trial simulations for Bayesian adaptive trials using SAS and BUGS. Pharmaceutical Statistics, 2018, 17, 854-865.	0.7	4
11	Heavy Menstrual Bleeding. , 2018, , 653-662.		O
12	The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. International Journal of Gynecology and Obstetrics, 2018, 143, 393-408.	1.0	463
13	The impact of meridian balance method electro-acupuncture treatment on chronic pelvic pain in women: a three-armed randomised controlled feasibility study using a mixed-methods approach. British Journal of Pain, 2018, 12, 238-249.	0.7	4
14	Menstrual Disorders: The Need for Agreement on Terminologies and Classification of Causes of Abnormal Uterine Bleeding (AUB)., 2018,, 94-100.		0
15	New concepts for an old problem: the diagnosis of endometrial hyperplasia. Human Reproduction Update, 2017, 23, 232-254.	5.2	186
16	Development of a Bayesian response-adaptive trial design for the Dexamethasone for Excessive Menstruation study. Statistical Methods in Medical Research, 2017, 26, 2681-2699.	0.7	3
17	Best Practice Issue on â€~Abnormal Uterine Bleeding'. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2017, 40, 1-2.	1.4	3
18	Relevant human tissue resources and laboratory models for use in endometriosis research. Acta Obstetricia Et Gynecologica Scandinavica, 2017, 96, 644-658.	1.3	40

#	Article	IF	CITATIONS
19	Steroids Regulate CXCL4 in the Human Endometrium During Menstruation to Enable Efficient Endometrial Repair. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1851-1860.	1.8	7
20	Immunoprofiling of human uterine mast cells identifies three phenotypes and expression of $ER\hat{l}^2$ and glucocorticoid receptor. F1000Research, 2017, 6, 667.	0.8	20
21	Immunoprofiling of human uterine mast cells identifies three phenotypes and expression of $ER\hat{l}^2$ and glucocorticoid receptor. F1000Research, 2017, 6, 667.	0.8	26
22	Selective progesterone receptor modulators (SPRMs): progesterone receptor action, mode of action on the endometrium and treatment options in gynecological therapies. Expert Opinion on Therapeutic Targets, 2016, 20, 1045-1054.	1.5	61
23	Medical Management of Heavy Menstrual Bleeding. Women's Health, 2016, 12, 27-34.	0.7	50
24	Abnormal uterine bleeding. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2016, 34, 54-65.	1.4	121
25	Sex hormone replacement in ovarian failure – new treatment concepts. Best Practice and Research in Clinical Endocrinology and Metabolism, 2015, 29, 105-114.	2.2	44
26	Menstrual physiology: implications for endometrial pathology and beyond. Human Reproduction Update, 2015, 21, 748-761.	5.2	216
27	Re-definition and re-classification of menstrual disorders. Obstetrics, Gynaecology and Reproductive Medicine, 2013, 23, 331-336.	0.1	2
28	$ER\hat{I}^2$ -dependent effects on uterine endothelial cells are cell specific and mediated via Sp1. Human Reproduction, 2013, 28, 2490-2501.	0.4	27
29	Obesity and Menstrual Disorders. , 2013, , 525-535.		4
30	Mechanisms of disease: the endocrinology of ectopic pregnancy. Expert Reviews in Molecular Medicine, 2012, 14, e7.	1.6	24
31	Optimizing Reproductive Outcome in Children and Young People With Cancer. Journal of Clinical Oncology, 2012, 30, 3-5.	0.8	43
32	The FIGO systems for nomenclature and classification of causes of abnormal uterine bleeding in the reproductive years: who needs them?. American Journal of Obstetrics and Gynecology, 2012, 207, 259-265.	0.7	123
33	Chlamydia trachomatis Infection Increases Fallopian Tube PROKR2 via TLR2 and NFήB Activation Resulting in a Microenvironment Predisposed to Ectopic Pregnancy. American Journal of Pathology, 2011, 178, 253-260.	1.9	62
34	Novel Roles for Hypoxia and Prostaglandin E2 in the Regulation of IL-8 During Endometrial Repair. American Journal of Pathology, 2011, 178, 1245-1256.	1.9	66
35	The FIGO classification of causes of abnormal uterine bleeding in the reproductive years. Fertility and Sterility, 2011, 95, 2204-2208.e3.	0.5	290
36	FIGO classification system (PALMâ€COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. International Journal of Gynecology and Obstetrics, 2011, 113, 3-13.	1.0	1,066

#	Article	IF	Citations
37	The FIGO classification of causes of abnormal uterine bleeding. International Journal of Gynecology and Obstetrics, 2011, 113, 1-2.	1.0	49
38	Inflammatory pathways in endometrial disorders. Molecular and Cellular Endocrinology, 2011, 335, 42-51.	1.6	131
39	Progesterone: a pivotal hormone at menstruation. Annals of the New York Academy of Sciences, 2011, 1221, 88-97.	1.8	47
40	A Five-Year International Review Process Concerning Terminologies, Definitions, and Related Issues around Abnormal Uterine Bleeding. Seminars in Reproductive Medicine, 2011, 29, 377-382.	0.5	20
41	The Flexible FIGO Classification Concept for Underlying Causes of Abnormal Uterine Bleeding. Seminars in Reproductive Medicine, 2011, 29, 391-399.	0.5	29
42	An International Response to Questions about Terminologies, Investigation, and Management of Abnormal Uterine Bleeding: Use of an Electronic Audience Response System. Seminars in Reproductive Medicine, 2011, 29, 436-445.	0.5	14
43	Molecular and Cellular Causes of Abnormal Uterine Bleeding of Endometrial Origin. Seminars in Reproductive Medicine, 2011, 29, 400-409.	0.5	33
44	The FIGO Recommendations on Terminologies and Definitions for Normal and Abnormal Uterine Bleeding. Seminars in Reproductive Medicine, 2011, 29, 383-390.	0.5	250
45	Oestrogen and progesterone regulation of inflammatory processes in the human endometrium. Journal of Steroid Biochemistry and Molecular Biology, 2010, 120, 116-126.	1.2	106
46	Evidence of prokineticin dysregulation in fallopian tube from women with ectopic pregnancy. Fertility and Sterility, 2010, 94, 1601-1608.e1.	0.5	40
47	Cotinine Exposure Increases Fallopian Tube PROKR1 Expression via Nicotinic AChRα-7. American Journal of Pathology, 2010, 177, 2509-2515.	1.9	45
48	Regulation of 3Â-hydroxysteroid dehydrogenase type 1 and type 2 gene expression and function in the human ovarian surface epithelium by cytokines. Molecular Human Reproduction, 2009, 15, 379-392.	1.3	13
49	Cardiovascular Effects of Physiological and Standard Sex Steroid Replacement Regimens in Premature Ovarian Failure. Hypertension, 2009, 53, 805-811.	1.3	158
50	$3\hat{l}^2$ -Hydroxysteroid dehydrogenases and pre-receptor steroid metabolism in the human ovarian surface epithelium. Molecular and Cellular Endocrinology, 2009, 301, 65-73.	1.6	16
51	Review of the confusion in current and historical terminology and definitions for disturbances of menstrual bleeding. Fertility and Sterility, 2008, 90, 2269-2280.	0.5	72
52	Estrogen receptor related beta is expressed in human endometrium throughout the normal menstrual cycle. Human Reproduction, 2008, 23, 2782-2790.	0.4	44
53	Endometrial effects of hormonal contraception. Reproductive Medicine and Assisted Reproductive Techniques Series, 2008, , 601-612.	0.1	2
54	Abnormal uterine bleeding: getting our terminology straight. Current Opinion in Obstetrics and Gynecology, 2007, 19, 591-595.	0.9	38

#	Article	IF	Citations
55	A process designed to lead to international agreement on terminologies and definitions used to describe abnormalities of menstrual bleedinga^—. Fertility and Sterility, 2007, 87, 466-476.	0.5	163
56	Changes in vaginal morphology, steroid receptor and natural antimicrobial content following treatment with low-dose mifepristone. Contraception, 2007, 75, 271-280.	0.8	12
57	Endometrial effects of intrauterine levonorgestrel. Contraception, 2007, 75, S93-S98.	0.8	84
58	Regulation of human endometrial function: mechanisms relevant to uterine bleeding. Reproductive Biology and Endocrinology, 2006, 4, S5.	1.4	31
59	$11\hat{l}^2$ -Hydroxysteroid dehydrogenases in human endometrium. Molecular and Cellular Endocrinology, 2006, 248, 72-78.	1.6	54
60	Gene expression profiling of mid to late secretory phase endometrial biopsies from women with menstrual complaint. American Journal of Obstetrics and Gynecology, 2006, 195, 406-414.e7.	0.7	27
61	Mifepristone-induced amenorrhoea is associated with an increase in microvessel density and glucocorticoid receptor and a decrease in stromal vascular endothelial growth factor. Human Reproduction, 2006, 21, 2312-2318.	0.4	43
62	Progestogen only contraception and endometrial break through bleeding. Angiogenesis, 2005, 8, 117-126.	3.7	52
63	Chemokine expression is dysregulated in the endometrium of women using progestin-only contraceptives and correlates to elevated recruitment of distinct leukocyte populations. Human Reproduction, 2005, 20, 2724-2735.	0.4	25
64	Menorrhagia I: measured blood loss, clinical features, and outcome in women with heavy periods: a survey with follow-up data. American Journal of Obstetrics and Gynecology, 2004, 190, 1216-1223.	0.7	216
65	Menorrhagia II: is the 80-mL blood loss criterion useful in management of complaint of menorrhagia?. American Journal of Obstetrics and Gynecology, 2004, 190, 1224-1229.	0.7	124
66	Late reproductive sequelae of treatment for childhood cancer. , 2004, , 397-415.		0
67	Differential expression of the natural antimicrobials, beta-defensins 3 and 4, in human endometrium. Journal of Reproductive Immunology, 2003, 59, 1-16.	0.8	102
68	Hormonal contraception can suppress natural antimicrobial gene transcription in human endometrium. Fertility and Sterility, 2003, 79, 856-863.	0.5	70
69	Innate immune defences in the human endometrium. Reproductive Biology and Endocrinology, 2003, 1 , 116 .	1.4	167
70	Decidualization of the human endometrial stromal cell: an enigmatic transformation. Reproductive BioMedicine Online, 2003, 7, 151-161.	1.1	209
71	Antiprogestins as a model for progesterone withdrawal. Steroids, 2003, 68, 1061-1068.	0.8	42
72	Mifepristone: a novel estrogen-free daily contraceptive pill. Steroids, 2003, 68, 1099-1105.	0.8	36

#	Article	IF	Citations
73	A role for the androgen receptor in the endometrial antiproliferative effects of progesterone antagonists. Steroids, 2003, 68, 1033-1039.	0.8	36
74	Late reproductive effects of cancer treatment in female survivors of childhood malignancy. Current Obstetrics & Gynaecology, 2003, 13, 369-372.	0.2	5
75	Immunocytochemical assessment of mitotic activity with an antibody to phosphorylated histone H3 in the macaque and human endometrium. Human Reproduction, 2003, 18, 1185-1193.	0.4	118
76	Radiation damage to the uterus â€" Review of the effects of treatment of childhood cancer. Human Fertility, 2002, 5, 61-66.	0.7	164
77	Female reproductive potential post-treatment for childhood cancer. British Journal of Hospital Medicine, 2002, 63, 522-527.	0.3	2
78	Administration of an antiprogesterone up-regulates estrogen receptors in the endometrium of women using norplantâ,,¢: a pilot study. Fertility and Sterility, 2002, 77, 366-372.	0.5	45
79	Late reproductive sequelae following treatment of childhood cancer andoptions for fertility preservation. Best Practice and Research in Clinical Endocrinology and Metabolism, 2002, 16, 311-334.	2.2	124
80	Inflammatory mediators and endometrial function—focus on the perivascular cell. Journal of Reproductive Immunology, 2002, 57, 81-93.	0.8	40
81	Fibroblast Heterogeneity. American Journal of Pathology, 2001, 159, 925-935.	1.9	90
82	Hypothalamic–pituitary–ovarian dysfunction after prepubertal chemotherapy and cranial irradiation for acute leukaemia. Human Reproduction, 2001, 16, 1838-1844.	0.4	92
83	Morphological and functional changes in human endometrium following intrauterine levonorgestrel delivery. Human Reproduction, 2000, 15, 162-172.	0.4	87
84	Presence of secretory leukocyte protease inhibitor in human endometrium and first trimester decidua suggests an antibacterial protective role. Molecular Human Reproduction, 2000, 6, 191-196.	1.3	121
85	Factors of importance for implantation and problems after treatment for childhood cancer. , $1999, 33, 9-14$.		48
86	Effect of two antiprogestins (mifepristone and onapristone) on endometrial factors of potential importance for implantation. Fertility and Sterility, 1997, 67, 1046-1053.	0.5	74
87	Endocrinology: Immunohistochemical sex steroid receptor distribution in endometrium from long-term subdermal levonorgestrel users and during the normal menstrual cycle. Human Reproduction, 1993, 8, 1632-1639.	0.4	79
88	Physiology of Menstruation. , 0, , 29-44.		4